Biopharma Daily Stock Updates - 02/16/21

$XBI $160.16 -3% 📉


Covid Updates

$MRNA -3% Provides US vaccine supply update. MRNA has supplied 45.4 million doses of Moderna COVID-19 Vaccine to U.S. Government to date. source


Pipeline Updates

$CRTX -35% FDA puts clinical hold on ongoing phase 2/3 study due to hepatic AE's. Ph 3 remains on track to report data in Q4 2021. source


$KALA +10% Express Scripts, one of the leading pharmacy benefit managers (PBM) in the United States, has added EYSUVIS to its National Preferred, Basic and High Performance Formularies. source


$BLUE -38% Phase 1/2 and Phase 3 trials of LentiGlobin for sickle cell disease suspended by company after serious AE's reported of acute myeloid leukemia (AML). source


$SESN +8% BLA accepted and PDUFA target date set for 8/18/21 with priority review. FDA noted they do not anticipate holding an ADCOM meeting. source


Financial Updates

$GMDA -5% Offering


$YMAB -6% Offering


$VSTM +17% Baker Brothers holding. source



0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE